$エレベーション・オンコロジー(ELEV.US)$Data expected readout of EO-3021 data in the latter half of 2024, which could showcase the efficacy and safety of the anti-Claudin 18.2 antibody-drug conjugate in treating advanced cancers. Furthermore, preclinical data has shown that Elevation Oncology’s HER3-ADC candidate demonstrates significant antitumor activity, suggesting a strong foundation for future clinical evaluations
$エレベーション・オンコロジー(ELEV.US)$ NEWS Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 Elevation Oncology announces promising preclinical data for its HER3-ADC program, showcasing proof-of-concept results at AACR Annual Meeting 2024. The data demonstrates HER3-dependent cell killing and robust anti-tumor activity in solid tumors with high HER3 expression. The company aims to nominate a development candidate later in 2024.
$エレベーション・オンコロジー(ELEV.US)$$メリマック・ファーマシューティカルズ(MACK.US)$Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan MT Newswires· 2 mins ago Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution. The milestone payment was due from Ipsen after the US Food and Drug Administration approved Onivyde as a first-line...
2
2
報告
Jaguar8 :
I love the milestone payment but dissolution weighed it down
$エレベーション・オンコロジー(ELEV.US)$Elevation Oncology Announced That It Has Expanded Its Ongoing Phase 1 Clinical Trial Of EO-3021 Outside The United States, Dosing The First Patient In Japan
エレベーション・オンコロジーに関するコメント
Watching for data!
Furthermore, preclinical data has shown that Elevation Oncology’s HER3-ADC candidate demonstrates significant antitumor activity, suggesting a strong foundation for future clinical evaluations
Ten stocks with >300% YTD, Top 5 Gainers (30 Apr), and Quick Poll on the Fed interest rate decisions on 1 May 2024.
A quick recap for the month ending April 30, 2024.
Ten stocks with >300% YTD
$SWVLホールディングス(SWVL.US)$718.40%
$ルート(ROOT.US)$564.60%
$エレベーション・オンコロジー(ELEV.US)$561.08%
$ジャンワン(JAN.US)$554.05%
$GENEDXホールディングス(WGS.US)$520.71%
$コーバスファーマシューティカルズホールディングス(CRBP.US)$513.25%
$AGBAアクイジション(AGBA.US)$482.90%
$ジャナックス・セラピューティクス(JANX.US)$431.22%
$デイブ(DAVE.US)$4...
NEWS
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology announces promising preclinical data for its HER3-ADC program, showcasing proof-of-concept results at AACR Annual Meeting 2024. The data demonstrates HER3-dependent cell killing and robust anti-tumor activity in solid tumors with high HER3 expression. The company aims to nominate a development candidate later in 2024.
News
MT Newswires· 2 mins ago
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution.
The milestone payment was due from Ipsen after the US Food and Drug Administration approved Onivyde as a first-line...
Update
Still gonna hodl😉
2024 is MOOOOvin up nicely
MOOOOOOOOn!
まだコメントはありません